INTRODUCTION
Psoriasis is an inflammatory disease that affects 1-2% of the European and North American populations [1] . It typically presents with erythematous, scaly, raised, well-demarcated lesions on the scalp, trunk, and extensor surfaces; however, any body site can be involved. Up to 30% of patients suffer from an associated arthritis, known as psoriatic arthritis [2] , and patients with more extensive disease have diminished quality of life because of their skin and joint disease [3] . Furthermore, there are genetic links with conditions such as Crohn's disease as well as associations with obesity, type 2 diabetes, and cardiovascular mortality.
Current work is attempting to establish if psoriasis is a specific risk factor per se for these conditions or if factors such as increased smoking and alcohol use in patients with psoriasis accounts for such associations [4, 5] .
Typically, topical agents are first-line therapy for patients with mild psoriasis but generally ineffective for patients with more severe disease where a range of therapies, including phototherapy, systemic, and/or biological agents are often used. Current gold standard biologic therapies targeting anti-tumor necrosis factor (TNF) alpha and anti-interleukin-12p40 (anti-IL-12p40) have dramatically improved clinical outcomes in patients with psoriasis with improved short-term safety profiles (i.e., less organ specific toxicity) compared to widely used systemic agents. Despite this improvement, there are subpopulations of patients that are either nonresponders to currently available biological agents and/or have experienced diminishing therapeutic benefit over time [6, 7] . Moreover, current biologic agents still have the potential to cause significant side effects in a subset of patients with their longer-term safety yet to be fully evaluated [8] . In a phase 2 study for treatment in plaque psoriasis, four subjects showed a PASI 50 response in a 12-week treatment period compared to zero in the placebo arm [11] .
INTERLEUKINS 12 AND 23
IL-23 is a heterodimer consisting of a p19 and a p40 subunit. IL-23 regulates Th17 CD4 cells, which produce IL-17, a proinflammatory cytokine [12] . IL-12 is a heterodimer containing a p35 and p40 subunit. Production of IL-12 by phagocytes and dendritic cells links innate and adaptive immunity and activates signal transducer and activator of transcription 4 (STAT4), which increases the production of interferon gamma [1] . Studies have shown that in psoriatic lesions there is an overexpression of both IL-12 and IL-23. Many of these studies, however, used the presence of the shared p40
subunit to measure the expression of IL-12 and thus were unable to differentiate between the presence of IL-12 and IL-23 [13] [14] [15] [16] .
Ustekinumab is a human immunoglobulin
G1kappa monoclonal antibody to the p40 subunit, and therefore inhibits the actions of IL-12 and IL-23 ( 
INTERLEUKIN-17
While IL-23 is believed to be a key initiating cytokine in the development and maintenance of Th17 cells and a proven and effective target for psoriasis therapies, inhibiting the Th17 component of the IL-23/Th17 axis has also shown promising results [25] . The innate immune system release cytokines in response to environmental triggers, which leads to activation of myeloid dendritic cells. Myeloid dendritic cells, in turn, secrete IL-23, which drives Th17 differentiation (Fig. 1) . Th17 cells produce IL-22 and IL-17, a family of six cytokines (A-F) and five receptors, the levels of which have been shown to be increased in psoriatic skin [26] ( Fig. 1 
INTERLEUKIN-20/22
Although the immunopathogenesis of psoriasis through the Th17/IL-23 axis has been a primary focus for investigators, mechanisms inherent to keratinocyte proliferation and epidermal hyperplasia are also being studied. The IL-10 family of cytokines, specifically IL-20 and IL-22, play an integral role in this process by causing proliferation and altering differentiation of keratinocytes [28] . Additionally, IL-22 expression activates STAT3, which mediates acanthosis, a characteristic histologic finding in psoriasis lesions. Th17 cells secrete IL-22 ( Fig. 1) , which can induce expression of IL-20 that then acts as a secondary mediator [29] .
Thus, the process may also be T cell driven.
These cytokines, which are virtually undetectable in normal, healthy skin, are expressed at increased levels in psoriatic lesions [28] . Elevated levels of IL-22 in the blood have been correlated with disease severity.
Fezakinumab is a humanized monoclonal IgGy antibody to IL-22 being studied for treatment in rheumatoid arthritis and psoriasis. Safety and tolerability results of phase 1 trials for moderate to severe psoriasis are to be published in the near future [11] .
JANUS KINASE INHIBITORS
Cytokines that target STAT transcription factors activate JAK, a type of tyrosine kinase. By inhibiting JAK, the inflammatory action of T cells and cytokines such as IL-2, -6, -7, -9, -15, and -21 and interferons are suppressed.
Tofacitinib is a JAK inhibitor that targets JAK1 and JAK1/JAK3 specifically. It was developed as an immunosuppressant to treat rheumatoid arthritis, ulcerative colitis, Crohn's disease, and psoriasis, and to prevent transplant rejection [30] . In a phase 2a study of tofacitinib involving 59 patients with psoriasis, twice daily doses of 5, 10, 20, and 50 mg and once-daily doses of 60 mg of oral tofacitinib were compared versus placebo [11] . After 14 days of treatment, a dose-dependent reduction of Psoriatic Lesion Severity Sum compared to placebo was seen in all patients except those taking the 5 mg dose. Those patients taking 50 mg doses of oral tofacitinib twice daily showed a 71.8% reduction in PASI (Table 1) , whereas the placebo group showed a PASI reduction of only 11.5%. One hundred and ninety-seven patients with psoriasis participated in a subsequent phase 2b study, during which subjects were given 2, 5, or 15 mg of oral tofacitinib twice daily [11] . A PASI 75 response was seen in 25%, 40.8%, and 66.7%
respectively. Of those treated with placebo, only 2% achieved a PASI 75 response. Phase 3 studies in psoriasis using up to 10 mg twice daily dosing are currently being performed to confirm safety and efficacy [31] (Table 1) .
Baricitinib is an oral drug that selectively inhibits JAK1 and JAK2. During phase 1 studies, baricitinib was shown to be safe and well tolerated in 1-20 mg single doses and repeat doses of 2-20 mg. Current phase 2 trials are being performed to determine the efficacy of the drug, the effects of discontinuation, and the safety and efficacy of retreatment (Table 1) .
ASP-015K (Astellas Pharma US, Inc., Northbrook, IL, USA) is a JAK 3 inhibitor currently being studied in phase 2 trials [11] ( Table 1) . Only 10.3% of those on placebo had the same results [11] . In a subsequent phase 2b study, patients with psoriasis were given 10, 20, or 30 mg doses of apremilast twice daily. PASI 75 was seen in 11%, 29%, and 41%, respectively (Table 1 ). In this study, which involved 352 patients with moderate to severe psoriasis, eight serious adverse events occurred. None of these serious adverse events, however, were thought to be caused by apremilast [22] . Phase 3 trials are now being performed to test the safety and efficacy of two 30 mg doses of apremilast per day for 16 weeks.
PHOSPHODIESTERASE 4 INHIBITORS
Apremilast's potential for treatment of palmoplantar psoriasis and psoriatic arthritis are also being researched in phase 2 and phase 3 studies, respectively (Table 1) [11] .
CONCLUSION
Through increased understanding of the immunopathogenesis of psoriasis, major advances are continuing to be made in the realm of new biologic and oral treatments for plaque psoriasis. Specifically, the Th17/IL-23 axis has been a focus for investigators, resulting in many novel agents currently in clinical trials. The IL-23p19 inhibitors are of particular interest in targeted therapies as they are present at increased levels in psoriasis skin lesions and believed to contribute less in protecting against opportunistic infections and less likely to be responsible for MACE events than its IL-12 counterpart. Other cytokines such as IL-17 and IL-22 also play important roles in the pathogenesis of psoriasis and agent's inhibition of them has shown promising results [26, 28] . Moreover, oral agents such as JAK kinase and PDE4 inhibitors have proven effective in phase 2 and 3 clinical trials with a different safety profile and may offer options to patients averse to injectable agents. It is important to note, however, these new agents are potentially immunosuppressive and some are already known to increase the risk of serious infections. There is a need to be vigilant for longer-term side effects, including the potential for an increased risk of malignancy, the best method of doing so via established pharmacovigilance registries [32] .
Times are promising in the field of targeted therapies for psoriasis, and continued research into the immunopathogenesis of the disease will only lead to a growing armamentarium of safe and effective therapeutic agents.
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